John G.F. Cleland

TL;DR: The evidence is not sufficient to justify advising long-term aspirin therapy for patients with cardiovascular disease in general and for those with heart failure in particular, and unless there is an opportunity to randomize the patient into a study of antithrombotic strategies, then aspirin should be withdrawn or possibly substituted with an anticoagulant or an antiplatelet agent that does not block cyclooxygenase.

TL;DR: EHFSQ-1, comprises seven symptom clusters in patients with HF, and either summary factors or QoL scores can be used as an outcome measure, however, if the key question is 'what is this patient'sQoL?' rather than the reason why it is impaired, then a single, direct question may suffice.

TL;DR: In patients who already have clinical evidence of coronary atherosclerosis there is now clear evidence that several different lipid lowering agents can delay or even reverse the atherosclerotic process reducing the incidence of cardiovascular events and delaying mortality.

TL;DR: The risk of developing HF and of dying after an MI increases progressively with age, Regardless of age, most deaths after a MI are preceded by the development of HF.